# Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients

> **NCT03879876** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 12 (estimated)

## Conditions studied

- Pediatric Patients
- Any Type of Severe Combined Immunodeficiency (SCID)
- Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

## Interventions

- **DRUG:** Human T Lymphoid Progenitor (HTLP) injection

## Key facts

- **NCT ID:** NCT03879876
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-13
- **Primary completion:** 2023-09-03
- **Final completion:** 2025-06-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879876, "Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03879876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*